



Press release

SHL announces election of Board Members at AGM

Tel Aviv / Zurich, 24 February 2016 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced that at the Annual General Meeting of the Shareholders which was held today in Tel-Aviv, Israel, the following members of the Board were elected: Mr. Amnon Sorek, Mr. Eli Alroy, Mr. Uzi Blumensohn, Mr. Eyal Bakshi (new), Dr. Amir Lerman (new), Mr. Elon Shalev and Mr. Erez Alroy (new). These directors will serve until the next annual general meeting of the shareholders of the Company. Mr. Oren Most, Mr. Elad Magal and Mr. Ziv Carthy terminated their service as directors as of the Annual General Meeting. Also, the attending shareholders approved all other items on the AGM agenda.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.